Juno Therapeutics (JUNO) Stock Rating Lowered by Wells Fargo & Company
Wells Fargo & Company cut shares of Juno Therapeutics (NASDAQ:JUNO) from an outperform rating to a market perform rating in a report published on Tuesday morning, Marketbeat.com reports.
Other analysts have also issued reports about the stock. Citigroup reaffirmed a buy rating and set a $59.00 price target on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Cowen reissued a buy rating and issued a $49.00 price objective on shares of Juno Therapeutics in a research report on Friday, October 27th. Maxim Group reissued a buy rating and issued a $56.00 price objective (up from $34.00) on shares of Juno Therapeutics in a research report on Monday, October 9th. SunTrust Banks raised shares of Juno Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 2nd. Finally, Morgan Stanley reissued an equal weight rating and issued a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $45.48.
Shares of Juno Therapeutics (NASDAQ JUNO) opened at $44.68 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics has a 1 year low of $17.52 and a 1 year high of $63.45.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same period in the prior year, the firm posted ($0.57) earnings per share. The company’s quarterly revenue was up 115.4% compared to the same quarter last year. equities research analysts forecast that Juno Therapeutics will post -4.02 earnings per share for the current year.
In related news, EVP Robert Azelby sold 6,666 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now directly owns 79,998 shares in the company, valued at $4,395,890.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. 15.08% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. Utah Retirement Systems grew its stake in shares of Juno Therapeutics by 1.8% in the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 200 shares in the last quarter. State of Wisconsin Investment Board grew its stake in Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 210 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. Aperio Group LLC grew its stake in Juno Therapeutics by 4.2% during the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,194 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Juno Therapeutics by 9.5% during the third quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 1,328 shares in the last quarter. Institutional investors and hedge funds own 70.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://theolympiareport.com/2017/12/16/juno-therapeutics-juno-stock-rating-lowered-by-wells-fargo-company.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.